Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.

Palma M, Hansson L, Mulder TA, Adamson L, Näsman-Glaser B, Eriksson I, Heimersson K, Ryblom H, Mozaffari F, Svensson A, Gentilcore G, Österborg A, Mellstedt H.

Eur J Haematol. 2018 Mar 23. doi: 10.1111/ejh.13065. [Epub ahead of print]

PMID:
29569742
2.

Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.

Winqvist M, Palma M, Heimersson K, Mellstedt H, Österborg A, Lundin J.

Br J Haematol. 2017 Jul 5. doi: 10.1111/bjh.14836. [Epub ahead of print] No abstract available.

PMID:
28677818
3.

T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.

Palma M, Gentilcore G, Heimersson K, Mozaffari F, Näsman-Glaser B, Young E, Rosenquist R, Hansson L, Österborg A, Mellstedt H.

Haematologica. 2017 Mar;102(3):562-572. doi: 10.3324/haematol.2016.151100. Epub 2016 Dec 7.

4.

Nicotinamide inhibits endotoxin-induced monocyte tissue factor expression.

Ungerstedt JS, Heimersson K, Söderström T, Hansson M.

J Thromb Haemost. 2003 Dec;1(12):2554-60.

Supplemental Content

Loading ...
Support Center